leadf
logo-loader
viewActinium Pharmaceuticals Inc

Actinium Pharmaceuticals' Phase 3 blood cancer fighting drug results expected this fall

Actinium Pharmaceuticals Inc (OTCMKTS: ATNRW) CEO Sandesh Seth tells Proactive's Christine Corrado the biotech's flagship cancer fighting drug, Iomab-B, is currently in Phase 3, with results expected this fall, and an FDA filing expected in early 2020.

Seth says the drug targets elderly, acute myeloid leukemia patients, what he says is the deadliest form of blood cancer known to man.

Seth says the elderly can't tolerate chemotherapy drugs, and often die from the treatment. In contrast, Seth says Actinium's drug replaces chemo, with a bone marrow translate and cure rate of about 20%.

Quick facts: Actinium Pharmaceuticals Inc

Price: 10.41 USD

NYSE:ATNM
Market: NYSE
Market Cap: $142.25 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Venture Minerals says Golden Grove North could host significant body of VMS...

Venture Minerals Limited's (ASX:VMS) Andrew Radonjic sat down with Proactive's Andrew Scott after confirming a volcanic massive sulphide (VMS) system with assays of up to 7% zinc in its maiden drilling at the Orcus prospect within the Golden Grove North Project in WA. All three holes returned...

17 hours, 56 minutes ago

2 min read